Startups
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy).
Our platform is commercially validated by well over $1.0 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin.
These partnerships have rapidly translated Synaffix technology into 11 ADCs currently in development by our partners, where 3 of these are already available in Phase 1 clinical trials.
Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039.
Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy.
Our platform is commercially validated by well over $1.0 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin.
These partnerships have rapidly translated Synaffix technology into 11 ADCs currently in development by our partners, where 3 of these are already available in Phase 1 clinical trials.
Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039.
Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy.
Overview
Location
Netherlands, North Holland, Amsterdam
Employees
11-50
Founded date
2010
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| BioGeneration Ventures | biogenerationventures.com |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 7, 2025 | Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 | Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 Tue, Oct 07, 2025 17:00 CET Report this content Lund, Sweden, 7 October, 2025, Hansa Biopharma AB, “Hansa” (Nasdaq St... |
| Feb 6, 2023 | Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline | Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company AMSTERDAM, Feb. 6, 2023... |
| Jan 4, 2023 | Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program | Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B... |
| Jun 29, 2021 | Innovent Announces License Agreement with Synaffix in an ADC Technology Deal | SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| Jun 29, 2021 | Innovent Biologics : Announces License Agreement with Synaffix in an ADC Technology Deal | SAN FRANCISCO and SUZHOU, China, June 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
Reviews 0
FAQ about Synaffix
When was Synaffix founded?
Synaffix was founded in 2010.
Who has invested in Synaffix?
Parsers VC lists 2 investors of Synaffix, among them BioGeneration Ventures.
What has the press written about Synaffix?
Parsers VC has collected 6 articles mentioning Synaffix, among them “Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025” (Oct 7, 2025) and “Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline” (Feb 6, 2023).
Is Synaffix still active?
Yes, Synaffix is active; its latest activity on Parsers VC dates from Apr 8, 2026.